REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
24/01/2026
Voltar para busca
Dado oficial do USPTO
D DOMPÉ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
25/01/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 41, 42
Data de depósito
29/12/2014
Data de registro
24/01/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/04/2024
Última transação
25/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
09
Localização do titular
Milano, IT
Examinador
THOMAS, JULIE
Unidade examinadora
L70
Descrição da marca
The mark consists of a black-outlined, red hexagon with a white letter "D" in the center and the wording "DOMPÉ" in black to the right of the design.
Titulares e representantes
Titulares
DOMPE' FARMACEUTICI S.P.A.
DOMPE' FARMACEUTICI S.P.A.
Representantes
Kristen McCallion Fish & Richardson P.C.
Classificação técnica
Classes Nice
Classe 5Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceuticals; gelatin capsules sold empty for pharmaceuticals; ocular pharmaceuticals; pharmaceutical products for ophthalmological use ; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases also rare; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in tissue and organ transplantation also rare; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparationsanticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for treating diabetes also rare; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseasesanti-infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparationsan analgesic for human consumption taken orally; sanitary preparations for medical purposes; all-purpose disinfectants
Classe 41
Entertainment television news programme services in the field of pharmaceutical products and sanitary preparations for medical purposes broadcast over the internet; organizing community festivals featuring primarily pharmaceutical exhibition for medical purposes; arranging professional workshop and training courses in the field of pharmaceutical products and medicine for medical purposes; training services in the field of pharmaceutical and sanitary preparations for medical purposes; education serviceproviding tutoring in the field of pharmaceutical and sanitary preparations for medical purposes; providing information relating to organizing community cultural activities and contests
Classe 42
Conducting early evaluations in the field of new pharmaceuticals; conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmologytreatment of cancerdiabetesanalgesic preparationsnerve grow factorsoncologyorgan transplantationantibioticsrespiratory diseasesbone diseasesrare diseases; consulting services in the fields of biotechnologypharmaceutical research and developmentlaboratory testingmedical diagnosticsdrug development and pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; research and development of pharmaceuticals for the treatment of cancerdiabetesrespiratory diseasesbone diseasesrare diseasesocular disorders and diseases; research and development in the pharmaceutical and biotechnology fields
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
13/02/2025
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
01/02/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
08/01/2025
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
18/12/2024
XXCR
GENERIC MADRID TRANSACTION CREATED
18/12/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
03/12/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/12/2024
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
02/04/2024
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
02/04/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/04/2024
ES75
TEAS SECTION 71 & 15 RECEIVED
24/07/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/01/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/06/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/02/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/05/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/04/2017
FIMP
FINAL DISPOSITION PROCESSED
25/04/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/04/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
24/01/2017
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/11/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/11/2016
PUBO
PUBLISHED FOR OPPOSITION
08/11/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/10/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
19/10/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/10/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/09/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/09/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/09/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
28/09/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
30/06/2016
GNFR
FINAL REFUSAL E-MAILED
30/06/2016
CNFR
FINAL REFUSAL WRITTEN
30/06/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/06/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/06/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/06/2016
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/04/2016
RFNT
REFUSAL PROCESSED BY IB
18/12/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/12/2015
RFRR
REFUSAL PROCESSED BY MPU
01/12/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
26/11/2015
CNRT
NON-FINAL ACTION WRITTEN
25/11/2015
MAFR
APPLICATION FILING RECEIPT MAILED
14/11/2015
DOCK
ASSIGNED TO EXAMINER
10/11/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/11/2015
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
09/11/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/11/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace D DOMPÉ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.